We examined transcriptional changes in CD4 + T cells during blood-stage Plasmodium falciparum infection in individuals without a history of previous parasite exposure. Transcription of CXCL8 (encoding interleukin 8) in CD4 + T cells was identified as an early biomarker of submicroscopic P. falciparum infection, with predictive power for parasite growth. Following antiparasitic drug treatment, a CD4 + T-cell regulatory phenotype developed. PD1 expression on CD49b + CD4 + T (putative type I regulatory T) cells after drug treatment negatively correlated with earlier parasite growth. Blockade of PD1 but no other immune checkpoint molecules tested increased interferon γ and interleukin 10 production in an ex vivo antigen-specific cellular assay at the peak of infection. These results demonstrate the early development of an immunoregulatory CD4 + T-cell phenotype in blood-stage P. falciparum infection and show that a selective immune checkpoint blockade may be used to modulate early developing antiparasitic immunoregulatory pathways as part of malaria vaccine and/or drug treatment protocols.
Malaria remains a significant health problem in tropical and subtropical regions of the world. Despite substantial progress in disease control through vector management, use of insecticide-treated bed nets, and improved diagnosis and drug treatment, malaria is still responsible for more deaths than other parasitic diseases [1] . Critically, there is no licensed vaccine, and the emergence of artemisinin-resistant parasites in the Greater Mekong region represents a serious threat for disease treatment and control efforts. A major impediment to malaria eradication is our poor understanding about host immunity against the Plasmodium species that cause malaria in humans. This shortcoming in knowledge is especially apparent because of the poor performances of malaria vaccine candidates in malaria-endemic areas and the lack of consensus on how to generate long-lasting immunity in such areas.
Seminal studies performed >50 years ago showed that antiparasitic antibodies can protect against clinical malaria and control parasite growth [2] . However, these responses take years to develop in disease-endemic areas, occurring only after repeated exposure to malaria parasites [3] . Recent reports also highlight a requirement for antibodies with specific functional properties to mediate immunity [4] . The development of long-lived, antiparasitic memory B and plasma cells that produce these antibodies requires CD4 + T-cell help [5, 6] . Specialized CD4 + T-follicular helper (Tfh) cells are critical in this process by providing key cognate and soluble signals to B cells [7, 8] . Interferon γ (IFN-γ) production by Tbet + CD4 + T (Th1) cells is also important for generating specific antibody isotypes and activating phagocytic cells for increased antibody-and compliment-mediated removal of parasitized red blood cells (pRBCs) and for generating microbicidal molecules, such as reactive oxygen and nitrogen intermediates [9, 10] . However, these antiparasitic responses are often absent, suboptimal, or dysfunctional in individuals living in malaria-endemic areas [11] [12] [13] . The reasons are still unclear, but emerging evidence indicates parasite-induced development of atypical B cells, suboptimal Tfh cells, and Th1 cell responses characterized by autologous interleukin 10 (IL-10) production (type I regulatory [Tr1] cell responses), as well as the expression of inhibitory molecules [14] [15] [16] [17] [18] [19] . Therefore, unless these factors are addressed, malaria eradication will not be possible.
In this study, we examined CD4 + T-cell responses in healthy volunteers participating in controlled human malaria infection (CHMI) studies initiated with blood-stage Plasmodium falciparum. We identified CD4 + T-cell expression of CXCL8 (encoding IL-8) as an early molecular marker of blood-stage P. falciparum infection with predictive power for parasite multiplication. In addition, we found a CD4 + T-cell molecular signature characterized by expression of chemokine receptors and immune checkpoint molecules soon after antiparasitic drug treatment. These molecules supported the rapid acquisition of a regulatory, anti-parasitic CD4 + T-cell response following first exposure to P. falciparum.
METHODS

CHMI Studies
As part of clinical trials testing the efficacy of various antimalarial drugs in early-stage malaria, naive healthy individuals aged 18-56 years with no prior exposure to malaria parasites (Supplementary Table 1 ) underwent controlled infection with P. falciparum (clone 3D7; drug-susceptible strain). A total of 1800 or 2800 P. falciparum pRBCs were intravenously injected into individuals, and the blood parasite burden was measured daily by quantitative polymerase chain reaction (qPCR) analysis [20] , beginning 4 days after infection, and then twice daily, once a positive PCR result was obtained. Trial drug was administered 7 or 8 days after infection when the threshold for commencement of treatment (ie, ≥ 5000 parasites/mL) was reached. The parasite multiplication rate (PMR) was calculated from the time point before infection to time points after drug treatment (0-7 or 0-8 days after infection), as previously described [21] . Blood specimens were collected from naive volunteers (before infection) and from the same volunteers before treatment (7 or 8 days after infection, before antimalarial drug treatment), after treatment (13-15 days after infection), and 28 or 37 days after infection, into lithium heparin tubes for cellular processing and analysis. These studies were undertaken at Q-Pharm (Brisbane, Australia) under the approval of the QIMR Berghofer Human Research Ethics Committee. All studies were registered with the Australian and New Zealand Clinical Trial Registration scheme (ACTRN12613000565741 and ACTRN12612000323820) or with ClinicalTrials.gov (NCT02281344, NCT02867059, and NCT02783833).
Sample Processing
Peripheral blood mononuclear cells (PBMCs) were isolated as previously described [22, 23] . CD4 + T cells were isolated from PBMCs by magnetic-activated cell-sorting purification, using CD4 (L3T4) MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's guidelines, and stored at -80⁰C in RNAlater (Sigma Aldrich, St. Louis, MO).
Gene Expression Analysis
RNA was isolated using Qiashredders and the RNeasy Mini Kit in accordance with the manufacturer's instructions (Qiagen, Valencia, CA). The Nanodrop ND-1000 UV-Vis spectrophotometer (Thermo Fisher Scientific, Waltham, MA) was used to determine RNA concentration and quality, and RNA samples were assessed using the nCounter XT Gene Expression Assay on the nCounter platform (NanoString Technologies, Seattle, WA), according to the manufacturer's guidelines.
Bioinformatic Analysis
NanoString data were analyzed using nSolver analysis software, version 3.0 (NanoString Technologies) for quality control, background subtraction, and normalization. Default settings were used for all samples (Supplementary Table 2 ). In summary, after quality control assessment and background subtraction, counts were normalized using the geometric mean values for housekeeping genes. These normalized counts served as inputs for differential gene expression analysis using the R package edge R [24, 25] . In brief, a generalized linear model was used in which both time and volunteer served as explanatory variables. Subsequently, likelihood ratio testing was used to determine significantly (α = 0.05) differentially expressed genes between specific time points. Principle component analysis was performed using the R packages FactoMineR and factoextra [26, 27] . R, version 3.4.3 (codename Kite-Eating Tree), was used for all NanoString analyses (R Foundation for Statistical Computing, Vienna, Austria; available at: https://www.R-project.org).
Flow Cytometry
Flow cytometry of PBMCs was performed as previously described [22] . Supplementary Table 3 shows antibodies purchased from either Biolegend (San Diego, CA) or BD Biosciences. The Zombie Aqua Fixable Viability Kit (Biolegend) was used to measure cell viability.
Antibody Blockade
Human PBMCs were cultured with pRBCs and blocking antibodies, as previously described [22, 23] . Supernatant was harvested from cultures at 72 hours and stored at -20⁰C. The following antibodies were used: human anti-CTLA4 (clone L3D10; Biolegend) and isotype control mIgG1κ (clone MOP-C21; Biolegend), human anti-LAG3 (Lag3.5-g4p.20120227; Bristol-Myers Squibb [BMS], New York, NY) and isotype control IgG4 (g4P-DT1D12; clone 4A09_RAS_Ab; BMS), human anti-TIM3 (clone F38-2E2; eBiosciences) and isotype control mIgG1κ (GIR-208; Leico Technologies), and human anti-PD1 (Nivolumab; BMS-936558; BMS) and isotype control human IgG4 (clone 1D12; BMS).
Cytokine Analysis
Cytokine concentrations were measured using the Inflammatory Cytokine CBA Kit, the Th1/Th2/Th17 Cytokine Kit, and IFN-γ and IL-10 Flex Sets (BD Biosciences), according to manufacturer's guidelines.
DNA Methylation Analysis
DNA was isolated from CD4 + T cells purified from PBMCs by the magnetic-activated cell-sorting technique, using an AllPrep DNA/RNA mini kit (Qiagen). DNA quality was assessed with a Nanodrop ND-1000 UV spectrophotometer (Thermo Scientific). The Illumina methylation EPIC BeadChip platform (Illumina, San Diego, CA) was used to examine DNA methylation of PDCD1 in CD4 + T cells isolated from volunteers before and 7 days after P. falciparum infection. The assay was performed on paired samples by Macrogen (Seoul, Korea). Array data were exported using Illumina GenomeStudio, version 2011.1 (Methylatioin Module, version 1.9.0). Probes with a detection P value of >.05 in >25% of samples and probes with missing values were removed from analysis. Data was then processed in R (with background correction, beta-mixture quantile normalization, and M value transformation). Differential methylation was tested by the Tukey honest significant difference test and corrected for multiple tests. A probe was considered differentially methylated if the adjusted P value was < .05 and the β value difference was >0.20.
Statistical Analysis
Results were analyzed using GraphPad Prism software v7.2 (GraphPad), unless otherwise specified. Specific tests used are described in the figure legends.
RESULTS
CD4 + T-Cell CXCL8 Expression Is a Molecular Marker for Submicroscopic P. falciparum Blood-Stage Infection
To better understand the behavior of CD4 + T cells during blood-stage P. falciparum infection, we examined PBMCs from volunteers participating in CHMI studies. Subjects were infected with blood-stage P. falciparum and treated with a trial drug at 8 days after infection, when blood parasite levels exceeded 5000 parasites/mL ( Figure 1A ). PBMCs were isolated from naive volunteers (before infection), before treatment (8 days after infection, prior to administration of drug treatment), after treatment (15 days after infection), and 28 days after infection. PBMCs were isolated, and CD4 + T cells were assessed by flow cytometry ( Figure 1B ). Despite variation in individual CD4 + T-cell numbers ( Figure 1C ), major CD4 + T-helper cell subset frequencies remained relatively constant over the course of infection and recovery ( Figure 1D ).
CD4 + T cells were isolated, and RNA was extracted for the digital measurement of 130 selected immune-related gene transcripts and 5 housekeeping control genes (Supplementary Table 4 ). A comparison of naive (baseline; before infection), before drug treatment (acute infection; days 7-8 after infection) and after drug treatment (resolving infection; days 13-14 after infection) CD4 + T cells revealed a number of changes in gene expression (Figure 2) . Few of these changes occurred before drug treatment, with only 4 differentially expressed genes identified between baseline and pretreatment samples, including a significant increase in TNFSF10, GZMB, HLA-DRA, and CXCL8 (IL8) messenger RNA (mRNA) levels (Figure 2A ). Given the dramatic increase in CD4 + T-cell CXCL8 mRNA at a time when the blood parasitemia level was submicroscopic, we examined whether there was any association with PMR. Interestingly, we observed a significant, negative correlation (R = -0.63, P = .03) between the fold change in CD4 + T-cell CXCL8 mRNA level (baseline vs infected samples) and PMR ( Figure 3A) . No significant correlations between changes in CD4 + T-cell TNFSF10, GZMB, and HLA-DRA mRNA and PMR were found (data not shown). We also measured IL-8 in plasma and found a small but significant (P < .001) increase before treatment ( Figure 3B ). However, in contrast with the change in CD4 + T-cell CXCL8 mRNA level, we found a significant, positive correlation (R = 0.44, P = .04) between PMR and plasma IL-8 levels before treatment ( Figure 3C ), possibly reflecting contributions of IL-8 production by other cell sources. Thus, early CD4 + T-cell CXCL8 expression was a molecular marker of submicroscopic P. falciparum blood-stage infection with predictive power for early parasite multiplication.
Control of P. falciparum Infection Is Associated With a CD4 + T-cell Signature Characterized by Inflammatory and Immunoregulatory Gene Expression
Differentially expressed gene analysis comparing CD4 + T cells at all 3 time points showed that most transcriptional changes occurred after drug treatment (Figure 2 and Figure 4A ). Furthermore, principal component analysis (PCA) showed baseline and pretreatment samples to be clustered together, whereas posttreatment samples were separated along dimension 1 ( Figure 4B ). The top 50 genes contributing to dimension 1 ( Figure 4C ) included genes such as IFNG and TBX21, which encode IFN-γ and Tbet, respectively [28] . PCA also showed that individual samples within each time point were separated along dimension 2, indicating that the genes contributing to this dimension influence donor variation. These genes included MAF and EOMES, which encode transcription factors associated with Tr1 cells ( Figure 4C ) [29] [30] [31] . Pathway analysis using genes differentially expressed between pretreatment and posttreatment time points revealed major Th cell pathways linked to GZMH   GZMH  IL21  CXCR6  CCR5  IL12RB2  IFNG  CD38  LAG3  GZMA  HAVCR2  IL1RL1  TBX21  GZMB  CXCR3  PDCD1  GZMK  CCL5  KLRG1  PRF1  JAK2  CTLA4  IL18R1  GFI1  ITGAE  ICOS  IL32  CD4  TGFB1  NFATC2  CD3D  JAK3  JAK1  CD40LG  CD27  AHR  ITK  CD226  GATA3  STAT6  CD96  TIGIT  RUNX1  CD45RA  SOCS5  CCR7  S1PR1  BACH2  IL4R  KLF2  CXCR5  IL21R  JUNB   IFNG  IL21  CXCR6  IL12RB2  CCR5  CD38  IL1RL1  PDCD1  LAG3  GZMA  GZMK  TBX21  CXCR3  HAVCR2  CCL5  CTLA4  KLRG1  ITGAE  IL18R1  IL2RB  PRF1  GFI1  IL32  JAK2  ICOS  CD3D  IL7R  STAT3  CD226  GATA3  TNFSF10  ITK  STAT4  S1PR1  RUNX1  AHR  TNF  KLF2  CD40LG  IL4R  SOCS5  SOCS1  BACH2  RORC  CD45RA  CCR7  IL21R  CXCR5  CD244  HLA-DRA  PTGDR2  NT5E  CCR9  FOS Inflammatory and immunoregulatory CD4 + T-cell signature associated with Plasmodium falciparum infection. NanoString analysis was used to digitally assess differential expression of genes from CD4 + peripheral blood mononuclear cells isolated from whole-blood specimens at baseline (day 0), before treatment (7-8 days after infection), and after treatment (13-14 days after infection). Log 2 fold changes in gene expression before treatment vs baseline(A), after treatment vs before treatment (B), and after treatment vs baseline (C). Data are from cohorts 1, 2, and 3 (n = 12) and reflect mean values.
the antiparasitic immune response during Plasmodium infection ( Figure 4D ). These included T-helper cell differentiation, ICOS-ICOSL signaling in T helper cells, and IL-10 signaling. Of note, CXCL8 was the most downregulated gene during this period and returned to preinfection levels ( Figure 2B ). Expression of several Th1 cell-associated genes was upregulated after treatment (IL12RB2, TBX21, and IFNG), as was expression of cytotoxicity genes (GZMH, GZMA, and PRF1), suggesting a proinflammatory gene signature. However, increased expression of immune checkpoint genes (LAG3, PDCD1 [encoding PD1], HAVCR3 [encoding TIM3], and CTLA4) was also observed, indicating a rapidly developing immunoregulatory signature following drug treatment. These molecules have previously been identified as inhibitory receptors in rodent models of malaria and other human malaria studies [32] [33] [34] [35] . We also found significant changes in chemokine receptor gene expression following drug treatment, including increased expression of CXCR6, CCR5, and CXCR3 and decreased expression of CXCR5 and CCR9, indicating alterations to tissue-homing properties of CD4 + T cells during resolution of infection.
Changes in Immune Checkpoint and Chemokine Receptor Expression by CD4 + T-Cell Subsets
We next examined peripheral blood CD4 + T-cell subsets for expression of selected immune checkpoint and chemokine receptors, using flow cytometry. Specifically, we measured PD1, LAG3, TIM3, CTLA4, CCR5, and CXCR3 expression by CD4 + T cells prior to infection and during acute infection, resolving infection, and 32 days after infection ( Figure 5 ). We found, as indicated earlier by mRNA levels, frequencies and intensities (median fluorescence intensity [MFI] and fluorescence index) of these markers were increased with resolution of infection (ie, after treatment), with the exceptions of LAG3, which was reduced in frequency and fluorescence index after drug treatment ( Figure 5B and 5D) , and CXCR3 and PD1, which had reduced MFIs ( Figure 5C Figure 6B ), suggesting that PMR influences the phenotype and, potentially, function of Tr1 cells during parasite clearance. Interestingly, early (ie, before treatment) blockade of PD1 signaling but not of CTLA4, LAG3, or TIM3 signaling (data not shown) in PBMCs restimulated with P. falciparum antigen in vitro enhanced antigen-specific production of IFN-γ ( Figure 7A ) and IL-10 ( Figure 7B) . Although, the cell populations producing these cytokines were not identified, Tr1 cells have been shown to coproduce both cytokines in previous studies using this cell culture system [36] . One potential reason for the selective impact of PD1 blockade but not inhibition of other immune checkpoints was that PDCD1 was poised for early expression in CD4 + T cells following encounter with parasite antigen, owing to changes in DNA methylation. However, we found no significant changes in DNA methylation in CpG sites located in PDCD1 in CD4 + T cells in the first 7 days of infection ( Figure 7C ).
DISCUSSION
In this study, we identified a distinct CD4 + T-cell molecular signature induced by submicroscopic P. falciparum infection. This signature included upregulation of inflammatory molecules as early as days 7 or 8 after infection (ie, before treatment), and induction of a regulatory phenotype with infection resolution after drug treatment. The genes upregulated early in infection (CXCL8, CCL4, HLA-DRA, and TNFSF10) are known to play roles in chemotaxis, inflammation, and antigen presentation [37] [38] [39] [40] . We also found increased plasma IL-8 levels corresponding to increased CD4 + T-cell CXCL8 expression.
Interestingly, IL-8 was also upregulated in young children with malaria from areas of endemicity [41] and in adults after long periods of no exposure [42] , suggesting IL-8 is an early marker of malaria in individuals with low parasite exposure. This may T -H e lp e r C e ll D i e r e n t ia t io n H e p a t ic F ib r o s is / H e p a t ic S t e ll a t e C e ll A c t iv a t io n C o m m u n ic a t io n B e t w e e n I n n a t e a n d A d a p t iv e I m m u n e C e ll s C r o s s t a lk B e t w e e n D e n t r ic C e ll s a n d N a t u r a l K il le r C e ll s CD45R0  CCL5  RORC  CD45RA  CD8A  IL23R  PRF1  NFATC2  EOMES  IL2RB  GNLY  CXCR5  GZMK  CCR6  KLRG1  IFNGR1  GZMA  SELL  FAS  IL32  CCL4  JUN  CD300A  FOS  CCR7  PRDM1  ITGA4  TNF  GZMH  IL10RA  CD244  RUNX3  CD28  TGFB1  CXCR6  AHR  GF11  BACH2  BCL6  CD69  CXCR3 1. CD96  CD30  IFNG  STAT5B  JAK1  CD3G  CD38  KLF2  S1PR1  CD27  ITK  TBX21  IL4R  IL12RB2  CD4  CCR5  CD40LG  STAT6  CXCR6  PDCD1  SOCS5  IL7R  IL21  GATA3  BACH2  JAK3  TGFB1  STAT3  LAG3  CCR7  HAVCR2  STAT5A  IL1RL1  STAT4  LCK  CD226  IL23A  CXCR3  ADORA2A  GZMA  IL21R  NFATC2  PTGER2  TIGIT  SELL  ITGAE  AHR  IL18R1 Figure 4. Change in CD4 + T-cell gene expression during Plasmodium falciparum infection. NanoString analysis was used to digitally assess differential expression of genes from CD4 + peripheral blood mononuclear cells, which were isolated from whole-blood specimens collected at baseline (day 0), before treatment (7-8 after infection) and after treatment (13-14 days after infection). A, Heat map of significantly differentially expressed genes. Blue represents a z score of -4, and red represents a z score of 4. B, Principal component analysis of differentially expressed genes across the 3 time points in each subject. C, Top 50 genes that exceeded the expected average contribution (red line) toward dimensions 1 (Dim1) and 2 (Dim2) in panel B. D, Top 10 canonical pathways significantly associated with genes differentially expressed after treatment in comparison to before treatment, by -log(P) and percentage of pathway genes upregulated or downregulated in the sample. Data are for cohorts 1, 2, and 3 (n = 12) and were analyzed using Ingenuity Pathway analysis (Qiagen). IL-10, interleukin 10; IL-12, interleukin 12.
be especially relevant for young children who have had minimal exposure to Plasmodium and for military personnel and civilian travelers who are infrequently exposed. IL-8 levels may act as a preliminary identification of malaria in these individuals when the blood parasitemia level is submicroscopic. Interestingly, we also found a positive correlation between plasma IL-8 levels and PMR, indicating that IL-8 is not only a marker of early infection but may also contribute to infection progression and, consequently, disease severity, as supported by previous genetic and biochemical studies [43, 44] . Despite the inflammatory milieu often seen in acute malaria, CD4 + T-cell responses are generally suboptimal, characterized by exhaustion and terminal differentiation, with an inability to efficiently form immunological memory [12, 13] . In this study, we found a prominent regulatory signature within the CD4 + T-cell population that may contribute to this constrained immune response. Immune checkpoint molecules, including PD1, CTLA4, TIM3, and LAG3, were upregulated at the mRNA and protein levels in association with drug-mediated resolution of infection. Additionally, pathway analysis indicated changes in IL-10 signaling during this time. IL-10 is important for limiting immune pathology caused by proinflammatory, antiparasitic immune responses [45] . Tr1 cells are a major source of this cytokine in parasitic infections [16, 45, 46] , and PD1, CTLA4, TIM3, and LAG3 are also known to regulate antigen-specific T-cell responses and can be markers of cellular exhaustion in infectious diseases, including malaria [18, 32, [47] [48] [49] . We also observed increased expression of several genes associated with cytolytic activities after drug treatment, including granzymes A, B, H, and K and perforin, as has previously been reported for a subset of cytolytic CD38 + CD4 + T cells in CHMI studies that were positively associated with increased control of parasite growth [50] . It should be noted that none of the 4 different drugs used in our studies (for details, studies can be accessed via clinical trials identifiers specified in Methods) have a known effect on human lymphocyte function in the doses tested.
Blockade of several immune checkpoint molecules, as well as IL-10, has previously been shown to improve antiparasitic T-cell responses [18, 32, [47] [48] [49] . We found that blocking PD1 before treatment, when the blood parasitemia level was submicroscopic, enhanced antigen-specific IFN-γ and IL-10 responses. This occurred despite no significant increase in expression in CD4 + T-cell PD1 mRNA or cell surface protein at this time, suggesting that PDCD1 expression is poised and rapidly activated following encounter with parasite antigen. However, we found no change in the level of DNA methylation of PDCD1 over the first 7 days of P. falciparum infection, indicating other epigenetic modifications may be responsible for the effects of PD1 blockade. It is also possible that the frequency of cells responding to PD1 inhibition was too small to allow detection of changes in CD4 + T-cell PDCD1 methylation. Alternatively, the changes in cytokine production after cg20805133  cg17322655  cg03889044  cg27051683  cg00795812  cg02122525  cg25890838  cg18096388  cg15139720  cg10994870  cg09031938  cg21670983  cg04789125  cg15153118  cg20601192  cg24984297  cg25798782  cg16720890  cg06291111  cg09319815  cg07281781  cg10057601 concentrations in cell culture supernatants from peripheral blood mononuclear cells isolated from volunteers 7 days after infection and cultured for 72 hours with either medium alone, uninfected red blood cells (nRBCs), or Plasmodium falciparum-infected RBCs (pRBCs), as well as either nivolumab (αPD1) or its isotype control (ISO-PD1). Data are from cohort 5 (n = 8). *P ≤ .05 and **P ≤ .01, by the Wilcoxon matched-pairs signed rank test. C, DNA methylation levels in PDCD1 of CD4 + T cells before infection (day 0) and 7 days after P. falciparum infection (prior to drug treatment). Methylation was measured at CpGs located 1500 base pairs (bp) and 200 bp from the gene translation start site (TSS1500 and TSS200, respectively), 5' untranslated region (UTR), first exon, gene body, and 3' UTR, where a score of 1 means complete methylation and a score of 0 means no methylation. Data are from cohorts 7 and 8 (n = 9 paired samples). PD1 blockade in our ex vivo antigen restimulation assays may have resulted from effects on other cells in the PBMC cultures. Regardless, these results show that conditioning of cells toward suboptimal functionality begins early in infection.
Interestingly, we found that changes in expression of PD1 by Tr1 cells after drug-mediated control of parasites negatively correlated with PMR up to the time of antiparasitic drug treatment, suggesting that the rate of parasite growth influences the polarization of T cells toward a regulatory phenotype and, in particular, Tr1 cells. This is noteworthy since PD1 blockade enhanced production of IFN-γ and IL-10, cytokines that are commonly coproduced by Tr1 cells [15, 39, 51] . Despite LAG3 being a marker of Tr1 cells [52] , blocking LAG3 ex vivo in pretreatment samples did not impact antigen-specific cytokine production. Of note, attempts to block LAG3, as well as PD1, CTLA4, and TIM3, on PBMCs in ex vivo antigen restimulation assays after antiparasitic drug treatment (ie, on days 13-15 after infection) failed to result in any consistent change in cytokine production across cohorts. However, changes in cytokine production by individuals following selected immune checkpoint blockade were observed. It is also possible that effects may have occurred in specific immune cell populations but were not detected because we only measured cytokine production by all PBMCs in our assays. Together, these data indicate that despite increased expression of several known immune checkpoint molecules soon after antiparasitic drug treatment, their influence on subsequent development of antiparasitic immunity is highly variable across individuals, with the exception of CD4 + T-cell PD1 expression in response to parasite antigen exposure early in infection. However, as mentioned above, we cannot exclude the possibility that specific immune cell subsets were impacted by immune checkpoint blockade in a more consistent manner.
Anti-PD1 therapy is used to treat cancer by improving T-cell function to promote clearance of diseased tissue [53] . Since early PD1 blockade enhanced antigen-specific cytokine production in our ex vivo cell culture system, blockade early in infection may be used to reduce the regulatory and exhausted phenotype seen in T cells in malaria and improve not only parasite clearance but also the development of long-term memory. This could be considered as a novel immunomodulatory intervention in at-risk groups. Alternatively, this strategy may have potential for improving vaccine efficacy, whereby PD1 blockade could be used in combination with malaria vaccination. This approach has been found to improve efficacy of both viral and cancer therapeutic vaccines via improvement of CD8 + T-cell function [54, 55] and may prove beneficial for Plasmodium vaccine regimens where protection is suboptimal and wanes within a few years. However, the increase in IL-10 production observed following PD1 blockade may be problematic given its potent antiinflammatory properties. Therefore, strategies to overcome this effect on IL-10 production while boosting selected antiparasitic activity may be required.
In summary, we found that P. falciparum infection influences CD4 + T-cell phenotype early in infection. CD4 + T-cell CXCL8 transcription may be used to identify P. falciparum infection early, particularly in patients with low P. falciparum exposure. Additionally, we show that early infection influences later CD4 + T-cell response, inducing a regulatory phenotype that can be manipulated by early PD1 blockade. Together, these findings highlight the need to incorporate strategies that avoid or overcome dominant antiparasitic regulatory immune responses established during prior infection into malaria vaccine and drug treatment protocols.
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